Praxis Precision Medicines Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Praxis Precision Medicines Inc
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
/ 
Frequently asked questions
To buy Praxis Precision Medicines Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Praxis Precision Medicines Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Praxis Precision Medicines Inc is PRAX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Praxis Precision Medicines Inc has its primary listing on NASDAQ. You can trade Praxis Precision Medicines Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Praxis Precision Medicines Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Praxis Precision Medicines Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Praxis Precision Medicines Inc.